Are GLP-1 Drugs Safe and Effective for Overweight Patients With IBD?
In 16 obese IBD patients, GLP-1 drugs produced 6.2% weight loss at 6 months without triggering disease flares, though the sample was very small.
Quick Facts
What This Study Found
Sixteen obese patients with IBD (9 Crohn's disease, 7 ulcerative colitis) received semaglutide 1.0 mg or liraglutide 3.0 mg for obesity. Their median starting BMI was 35.
At 6 months, median weight change was -6.2%. 58.3% (7 of 12 evaluable patients) achieved at least 5% weight loss. IBD activity scores showed no significant changes during follow-up, meaning the drugs did not trigger disease flares.
Side effects were mild. Nausea was the most common at 13.3%. One patient discontinued due to diarrhea. No serious adverse events were reported.
Key Numbers
- 16 patients (9 Crohn's, 7 ulcerative colitis)
- Median baseline BMI: 35
- Median weight change at 6 months: -6.2%
- 5% weight loss achieved: 58.3% (7/12)
- Nausea: 13.3%
- 1 withdrawal due to diarrhea
- IBD activity: no significant changes
How They Did This
Retrospective case series of consecutive IBD patients who received GLP-1 drugs (semaglutide 1.0 mg or liraglutide 3.0 mg) for obesity between 2019 and 2021. The coprimary endpoints were percentage weight change at 6 months and proportion achieving 5% or more weight loss. IBD activity and safety were monitored.
Why This Research Matters
Obesity is common in IBD patients and worsens their disease outcomes. But GLP-1 drugs have not been studied in IBD patients, raising concerns that GI side effects could worsen IBD symptoms or trigger flares. This small study provides the first evidence that GLP-1 drugs are safe and effective for weight loss in this population.
The Bigger Picture
GLP-1 drugs have not been studied in IBD patients, creating uncertainty about whether their GI side effects could worsen IBD. This small but important case series provides early reassurance.
What This Study Doesn't Tell Us
This is a very small retrospective case series with only 16 patients and no control group. The follow-up was only 6 months. IBD activity was assessed using clinical scores, not endoscopy or biomarkers, which could miss subclinical inflammation. The study cannot distinguish between semaglutide and liraglutide effects. Publication bias may favor reporting positive results.
Questions This Raises
- ?Would a larger study confirm the safety in IBD patients?
- ?Do GLP-1 drugs affect IBD inflammatory markers?
Trust & Context
- Key Stat:
- No IBD flares None of the 16 IBD patients experienced a disease flare while taking GLP-1 drugs for obesity
- Evidence Grade:
- Rated preliminary: very small retrospective case series with only 16 patients and 6 months follow-up. Important as first data in this population.
- Study Age:
- Published in 2024. First published evidence on GLP-1 drug safety in inflammatory bowel disease patients.
- Original Title:
- Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.
- Published In:
- Revista espanola de enfermedades digestivas, 116(9), 478-483 (2024)
- Authors:
- Ramos Belinchón, Clara, Martínez-Lozano, Helena, Serrano Moreno, Clara, Hernández Castillo, Diego, Lois Chicharro, Pablo, Ferreira Ocampo, Pablo, Marín-Jiménez, Ignacio, Bretón Lesmes, Irene, Menchén, Luis
- Database ID:
- RPEP-09117
Evidence Hierarchy
Frequently Asked Questions
Can IBD patients take Ozempic?
This small study (16 patients) found no IBD flares with GLP-1 drugs, but more research is needed before making broad recommendations.
Do GLP-1 drug GI side effects worsen IBD?
In this small study, GI side effects were modest and did not appear to trigger IBD flares. Only one patient stopped due to diarrhea.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09117APA
Ramos Belinchón, Clara; Martínez-Lozano, Helena; Serrano Moreno, Clara; Hernández Castillo, Diego; Lois Chicharro, Pablo; Ferreira Ocampo, Pablo; Marín-Jiménez, Ignacio; Bretón Lesmes, Irene; Menchén, Luis. (2024). Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.. Revista espanola de enfermedades digestivas, 116(9), 478-483. https://doi.org/10.17235/reed.2024.10305/2024
MLA
Ramos Belinchón, Clara, et al. "Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.." Revista espanola de enfermedades digestivas, 2024. https://doi.org/10.17235/reed.2024.10305/2024
RethinkPeptides
RethinkPeptides Research Database. "Effectiveness and safety of a GLP-1 agonist in obese patient..." RPEP-09117. Retrieved from https://rethinkpeptides.com/research/ramos-2024-effectiveness-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.